- Home
- CNEY vs QLGN Comparison
CNEY vs QLGN Comparison
Compare CNEY & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- QLGN
- Stock Information
- Founded
- CNEY 2018
- QLGN 1996
- Country
- CNEY China
- QLGN United States
- Employees
- CNEY N/A
- QLGN N/A
- Industry
- CNEY Major Chemicals
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- QLGN Health Care
- Exchange
- CNEY Nasdaq
- QLGN Nasdaq
- Market Cap
- CNEY 2.1M
- QLGN 2.4M
- IPO Year
- CNEY 2021
- QLGN N/A
- Fundamental
- Price
- CNEY $0.13
- QLGN $3.32
- Analyst Decision
- CNEY
- QLGN
- Analyst Count
- CNEY 0
- QLGN 0
- Target Price
- CNEY N/A
- QLGN N/A
- AVG Volume (30 Days)
- CNEY 504.6K
- QLGN 111.5K
- Earning Date
- CNEY 01-01-0001
- QLGN 04-15-2025
- Dividend Yield
- CNEY N/A
- QLGN N/A
- EPS Growth
- CNEY N/A
- QLGN N/A
- EPS
- CNEY N/A
- QLGN N/A
- Revenue
- CNEY $50,957,974.00
- QLGN N/A
- Revenue This Year
- CNEY N/A
- QLGN N/A
- Revenue Next Year
- CNEY N/A
- QLGN N/A
- P/E Ratio
- CNEY N/A
- QLGN N/A
- Revenue Growth
- CNEY N/A
- QLGN N/A
- 52 Week Low
- CNEY $0.12
- QLGN $2.96
- 52 Week High
- CNEY $1.60
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- CNEY 32.47
- QLGN 44.88
- Support Level
- CNEY $0.12
- QLGN $3.06
- Resistance Level
- CNEY $0.14
- QLGN $3.78
- Average True Range (ATR)
- CNEY 0.01
- QLGN 0.28
- MACD
- CNEY 0.00
- QLGN 0.03
- Stochastic Oscillator
- CNEY 28.97
- QLGN 19.80
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.